Jay Olshansky received his PhD in Sociology at the University of Chicago in 1984. He is currently a Professor in the School of Public Health at the University of Illinois at Chicago, Research Associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine, and Chief Scientist at Lapetus Solutions, Inc. The focus of his research to date has been on estimates of the upper limits to human longevity, exploring the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases. Dr. Olshansky is on the Board of Directors of the American Federation of Aging Research; he is the first author of The Quest for Immortality: Science at the Frontiers of Aging (Norton, 2001) and A Measured Breath of Life (2013); and co-edited Aging: The Longevity Dividend (Cold Spring Harbor Laboratory Press, 2015). In 2016, Dr. Olshansky was honored with the Donald P. Kent Award from the Gerontological Society of America, the Irving S. Wright Award from the American Federation for Aging Research, and he was named a  Next Avenue Influencer in Aging.

Joseph Baur is an Professor in the Department of Physiology at the Perelman School of Medicine and Associate Professor at the Institute for Diabetes, Obesity, and Metabolism of the University of Pennsylvania. He has made key contributions to the understanding of how metabolism and dietary factors influence longevity. In 2006, Dr. Baur and colleagues showed that a sirtuin activator, resveratrol, is able to improve insulin sensitivity and extend lifespan in obese mice. Recently, he lead a team that revealed a mechanism accounting for off-target effects of rapamycin, a drug that extends life in mice, but has been plagued by side effects that limit its utility in humans. His laboratory at Penn is currently focused on the use of small molecules to understand and mimic the life-extending effects of caloric restriction in rodents.

Dr. Baur has authored more that 30 peer-reviewed scientific publications, including seminal papers in Nature and Science. Findings from his work have been reported by leading news media, including the Wall Street Journal and the New York Times. Dr. Baur performed his postdoctoral studies with Dr. David Sinclair at Harvard Medical School, and holds a PhD from the University of Texas Southwestern Medical Center at Dallas.